{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:54:00Z","timestamp":1783475640769,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","worldneurosurgery.org","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.wneu.2018.02.188","type":"journal-article","created":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T19:42:37Z","timestamp":1520710957000},"page":"94-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study"],"prefix":"10.1016","volume":"115","author":[{"given":"Xiaohai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4287-5468","authenticated-orcid":false,"given":"Ming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjie","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2018.02.188_bib1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1172\/JCI20401","article-title":"Mechanisms for pituitary tumorigenesis: the plastic pituitary","volume":"112","author":"Melmed","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.wneu.2018.02.188_bib2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.wneu.2018.02.188_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrendo.2011.40","article-title":"Pathogenesis of pituitary tumors","volume":"7","author":"Melmed","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.wneu.2018.02.188_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.wneu.2018.02.188_bib5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/ncpendmet0290","article-title":"Management of resistant prolactinomas","volume":"2","author":"Olafsdottir","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.wneu.2018.02.188_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.wneu.2018.02.188_bib7","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jocn.2015.06.001","article-title":"Current indications for the surgical treatment of prolactinomas","volume":"22","author":"Smith","year":"2015","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.wneu.2018.02.188_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00006123-200208000-00025","article-title":"Pituitary surgery: transsphenoidal approach","volume":"51","author":"Jane","year":"2002","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2018.02.188_bib9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1530\/EJE-10-0629","article-title":"Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases","volume":"163","author":"Losa","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.wneu.2018.02.188_bib10","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1210\/jc.2010-0644","article-title":"Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience","volume":"95","author":"Raverot","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.wneu.2018.02.188_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-2007-1011796","article-title":"Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia","volume":"19","author":"Bronstein","year":"1987","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.wneu.2018.02.188_bib12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000123324","article-title":"Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas","volume":"34","author":"Lamberts","year":"1982","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.wneu.2018.02.188_bib13","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.wneu.2018.02.188_bib14","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1158\/0008-5472.CAN-12-3876","article-title":"AMPK: a contextual oncogene or tumor suppressor?","volume":"73","author":"Liang","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2018.02.188_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/emmm.201303737","article-title":"AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy","volume":"6","author":"Schiewer","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.wneu.2018.02.188_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11102-013-0488-y","article-title":"Interplay between the intracellular energy sensor AMP-activated protein kinase (AMPK) and the estrogen receptor activities in regulating rat pituitary tumor cell (GH3) growth in\u00a0vitro","volume":"17","author":"Tulipano","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.wneu.2018.02.188_bib17","doi-asserted-by":"crossref","first-page":"83657","DOI":"10.18632\/oncotarget.13274","article-title":"Refractory pituitary adenoma: a novel classification for pituitary tumors","volume":"7","author":"Dai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.wneu.2018.02.188_bib18","first-page":"421","article-title":"Management of medically refractory prolactinoma","volume":"117","author":"Molitch","year":"2014","journal-title":"J\u00a0Neuro-Oncology"},{"key":"10.1016\/j.wneu.2018.02.188_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","article-title":"Pharmacologic resistance in prolactinoma patients","volume":"8","author":"Molitch","year":"2005","journal-title":"Pituitary"},{"key":"10.1016\/j.wneu.2018.02.188_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11102-005-5086-1","article-title":"Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists","volume":"8","author":"Hamilton","year":"2005","journal-title":"Pituitary"},{"key":"10.1016\/j.wneu.2018.02.188_bib21","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3171\/2010.11.JNS101369","article-title":"Dopamine agonist-resistant prolactinomas","volume":"114","author":"Oh","year":"2011","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2018.02.188_bib22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jocn.2012.07.008","article-title":"Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas","volume":"20","author":"Bai","year":"2013","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.wneu.2018.02.188_bib23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11060-013-1351-8","article-title":"Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models","volume":"116","author":"Cao","year":"2014","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2018.02.188_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.29.02.06.dc05-1558","article-title":"Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin","volume":"29","author":"Bowker","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.wneu.2018.02.188_bib25","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.2337\/db13-0368","article-title":"AMPK: a target for drugs and natural products with effects on both diabetes and cancer","volume":"62","author":"Hardie","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.wneu.2018.02.188_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1095\/biolreprod.110.089722","article-title":"PRKA\/AMPK: integrating energy status with fertility in pituitary gonadotrophs","volume":"84","author":"Duval","year":"2011","journal-title":"Biol Reprod"},{"key":"10.1016\/j.wneu.2018.02.188_bib27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/AOG.0b013e31816a4ed4","article-title":"Use of metformin in polycystic ovary syndrome: a meta-analysis","volume":"111","author":"Creanga","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.wneu.2018.02.188_bib28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1095\/biolreprod.110.087023","article-title":"Metformin decreases GnRH- and activin-induced gonadotropin secretion in rat pituitary cells: potential involvement of adenosine 5' monophosphate-activated protein kinase (PRKA)","volume":"84","author":"Tosca","year":"2011","journal-title":"Biol Reprod"},{"key":"10.1016\/j.wneu.2018.02.188_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s12020-014-0428-2","article-title":"The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study","volume":"49","author":"Krysiak","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.wneu.2018.02.188_bib30","first-page":"8498","article-title":"Differential effects of estrogen and estrogen receptor antagonist, ICI 182 780, on the expression of calbindin-D9k in rat pituitary prolactinoma GH3 cells","volume":"7","author":"Wang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.wneu.2018.02.188_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1073\/pnas.1311121111","article-title":"Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK","volume":"111","author":"Liu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.wneu.2018.02.188_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jne.12231","article-title":"Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells","volume":"27","author":"Tulipano","year":"2015","journal-title":"J\u00a0Neuroendocrinol"},{"key":"10.1016\/j.wneu.2018.02.188_bib33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/ERC-14-0188","article-title":"The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas","volume":"21","author":"Monsalves","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.wneu.2018.02.188_bib34","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1158\/1078-0432.CCR-15-0288","article-title":"Targeting PI3K\/mTOR signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2018.02.188_bib35","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1158\/0008-5472.CAN-06-4447","article-title":"Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth","volume":"67","author":"Buzzai","year":"2007","journal-title":"Cancer Res"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875018304625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875018304625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T13:08:08Z","timestamp":1570885688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875018304625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":35,"alternative-id":["S1878875018304625"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2018.02.188","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2018.02.188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}